非手术治疗穆勒-韦斯病:西班牙的经验
Ángel Orejana1, Manuel Monteagudo2
1Orthopaedic and Trauma Department, Orthopaedic Foot and Ankle Unit, Hospital Universitario Quirónsalud Madrid, Spain; Faculty of Podiatric Medicine, Universidad Complutense Madrid, Spain.
Foot and ankle clinics
|January 29, 2026
概括
穆勒 - 怀斯病的治疗包括用于平脚形的整形器械. 定制带有门支和前器子的内可以减轻疼痛,通过减少脚压力来改善功能.
科学领域:
- 整形外科 整形外科 整形外科
- 足部医学是一门专业.
- 生物机械工程 生物机械工程
背景情况:
- 穆勒-韦斯病是一种罕见的退行性疾病,影响脚部.
- 它的特点是复杂的平脚形变形和关节关节炎.
- 之前关于非手术治疗的研究,特别是整形,是有限的,并显示偏见.
研究的目的:
- 讨论穆勒-斯病的非手术治疗策略.
- 专注于整形术在治疗平脚变形症中的作用.
- 为了强调基于疾病阶段的定制内设计的重要性.
主要方法:
- 对现有关于治疗穆勒 - 斯病的文献的综述.
- 对整形手术的分析,特别是带有中枢支的内和前置器的内.
- 讨论用于重新平衡足部结构的生物力学原理.
主要成果:
- 具有特定特征的内可以减少中关节的压力和压力.
- 内部鞋设计的定制对于有效的疼痛缓解和功能改善至关重要.
- 解决带有纵向塌的不对称骨关节炎需要有针对性的整形支.
结论:
- 整形治疗是对穆勒-韦斯病非手术治疗的关键组成部分.
- 量身定制的内设计,考虑到疾病的严重程度,对于最佳的结果至关重要.
- 需要进一步的研究来解决当前文献中的偏见,并完善治疗方案.
相关概念视频
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment
946
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
946
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
485
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
485
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
534
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
534
What is an Experiment?
18.1K
An experiment is a planned activity carried out under controlled conditions. The purpose of an experiment is to investigate the relationship between two variables. When one variable causes change in another, we call the first variable the explanatory or independent variable. The affected variable is called the response or dependent variable. In a randomized experiment, the researcher manipulates values of the explanatory variable and measures the resulting changes in the response variable. The...
18.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
551
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
551


